Attorney Docket: 148/50986

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: JOHANNES BARTHOLOMAEUS ET AL

Serial No.: TBA Group Art Unit:

Filed: Herewith Examiner:

Title: ORAL DOSAGE FORMS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97 and 1.98

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 CFR \$1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

English abstracts of the European and PCT Patent documents are submitted herewith.

The present Information Disclosure Statement is being filed

(1) no later than three months from the application's filing

date or (2) before the mailing date of the first Office Action

on the merits (whichever is later), and therefore no

certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

J, D. Evans

Registration No. 26,269

CROWELL & MORING, LLP

P.O. Box 14300

Washington, DC 20044-4300

Telephone No.: (202) 624-2500 Facsimile No.: (202) 628-8844